Bristol-Myers beats forecasts, as newer drugs deliver

Thu Jan 24, 2013 7:35am EST

(Reuters) - Bristol-Myers Squibb Co (BMY.N) reported better than expected quarterly sales and earnings, fueled by strong sales of newer treatments for leukemia, melanoma and diabetes.

The U.S. drugmaker on Thursday said it earned $925 million, or 56 cents per share, in the fourth quarter. That compared with $852 million, or 50 cents per share, in the year-earlier quarter.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.